Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication
Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (...
Gespeichert in:
Veröffentlicht in: | Helicobacter (Cambridge, Mass.) Mass.), 2024-03, Vol.29 (2), p.e13077-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 2 |
container_start_page | e13077 |
container_title | Helicobacter (Cambridge, Mass.) |
container_volume | 29 |
creator | Chen, Jing Zhang, Yan Min, Hanchen Zhi, Junli Ma, Shuyun Dong, Hongxia Yan, Jingshuang Chi, Xiaoyan Zhang, Xiaomei Yang, Yunsheng |
description | Background
A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT).
Methods
We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing.
Results
Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels.
Conclusion
Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota. |
doi_str_mv | 10.1111/hel.13077 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3048497949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3048497949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</originalsourceid><addsrcrecordid>eNp10b1u1TAYBmALgWgpDNwAssQCQ1r_5cQeUSkcpCOxdI--2M6JKydO7VgoGxMz18iV4ENKByS82PL36JXlF6HXlFzSsq4G6y8pJ03zBJ3TmvGq5o18Ws5E8kpwqc7Qi5TuCCE1F-o5OuNyJxnbyXP04-M6weg01gNMR5uwm_AyWHzMCy7XMXQuLIChX2zEnUtjXgZ8n8HEPHt7ohHmFcNk8OCOw6_vP01IFpsM_nHYh4j31jsdOtCnnHn1ITpcpsZpWFyYXqJnPfhkXz3sF-j2083t9b46fP385frDodKc8qailjJRK2mYULLrleqo0kpIwsASJUH2yphaAem1Ugx2lnZaMOgbxkHznl-gd1vsHMN9tmlpR5e09R4mG3JqORFSqEYJVejbf-hdyHEqj9sUaThnRb3fVPmplKLt2zm6EeLaUtKeumlLN-2fbop985CYu9GaR_m3jAKuNvDNebv-P6nd3xy2yN_hIpsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3048407332</pqid></control><display><type>article</type><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</creator><creatorcontrib>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</creatorcontrib><description>Background
A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT).
Methods
We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing.
Results
Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels.
Conclusion
Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</description><identifier>ISSN: 1083-4389</identifier><identifier>EISSN: 1523-5378</identifier><identifier>DOI: 10.1111/hel.13077</identifier><identifier>PMID: 38682268</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>16S rRNA sequencing ; Adolescent ; Adult ; Aged ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Bacteria - classification ; Bacteria - drug effects ; Bacteria - genetics ; Bacteria - isolation & purification ; Bismuth ; Bismuth - administration & dosage ; Bismuth - therapeutic use ; bismuth quadruple therapy ; Drug Therapy, Combination ; Eradication ; Feces ; Feces - microbiology ; Female ; Gastrointestinal Microbiome - drug effects ; gut microbiota ; Helicobacter Infections - drug therapy ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Helicobacter pylori - drug effects ; Helicobacter pylori - physiology ; high‐dose dual therapy ; Histology ; Humans ; Intestinal microflora ; Klebsiella ; Male ; Microbiota ; Microorganisms ; Middle Aged ; Proton Pump Inhibitors - administration & dosage ; Proton Pump Inhibitors - therapeutic use ; Relative abundance ; RNA, Ribosomal, 16S - genetics ; rRNA 16S ; Therapy ; Urea ; Young Adult</subject><ispartof>Helicobacter (Cambridge, Mass.), 2024-03, Vol.29 (2), p.e13077-n/a</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2024 The Authors. Helicobacter published by John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhel.13077$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhel.13077$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38682268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Min, Hanchen</creatorcontrib><creatorcontrib>Zhi, Junli</creatorcontrib><creatorcontrib>Ma, Shuyun</creatorcontrib><creatorcontrib>Dong, Hongxia</creatorcontrib><creatorcontrib>Yan, Jingshuang</creatorcontrib><creatorcontrib>Chi, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Xiaomei</creatorcontrib><creatorcontrib>Yang, Yunsheng</creatorcontrib><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><title>Helicobacter (Cambridge, Mass.)</title><addtitle>Helicobacter</addtitle><description>Background
A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT).
Methods
We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing.
Results
Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels.
Conclusion
Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</description><subject>16S rRNA sequencing</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteria - classification</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - genetics</subject><subject>Bacteria - isolation & purification</subject><subject>Bismuth</subject><subject>Bismuth - administration & dosage</subject><subject>Bismuth - therapeutic use</subject><subject>bismuth quadruple therapy</subject><subject>Drug Therapy, Combination</subject><subject>Eradication</subject><subject>Feces</subject><subject>Feces - microbiology</subject><subject>Female</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>gut microbiota</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - drug effects</subject><subject>Helicobacter pylori - physiology</subject><subject>high‐dose dual therapy</subject><subject>Histology</subject><subject>Humans</subject><subject>Intestinal microflora</subject><subject>Klebsiella</subject><subject>Male</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Middle Aged</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Relative abundance</subject><subject>RNA, Ribosomal, 16S - genetics</subject><subject>rRNA 16S</subject><subject>Therapy</subject><subject>Urea</subject><subject>Young Adult</subject><issn>1083-4389</issn><issn>1523-5378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10b1u1TAYBmALgWgpDNwAssQCQ1r_5cQeUSkcpCOxdI--2M6JKydO7VgoGxMz18iV4ENKByS82PL36JXlF6HXlFzSsq4G6y8pJ03zBJ3TmvGq5o18Ws5E8kpwqc7Qi5TuCCE1F-o5OuNyJxnbyXP04-M6weg01gNMR5uwm_AyWHzMCy7XMXQuLIChX2zEnUtjXgZ8n8HEPHt7ohHmFcNk8OCOw6_vP01IFpsM_nHYh4j31jsdOtCnnHn1ITpcpsZpWFyYXqJnPfhkXz3sF-j2083t9b46fP385frDodKc8qailjJRK2mYULLrleqo0kpIwsASJUH2yphaAem1Ugx2lnZaMOgbxkHznl-gd1vsHMN9tmlpR5e09R4mG3JqORFSqEYJVejbf-hdyHEqj9sUaThnRb3fVPmplKLt2zm6EeLaUtKeumlLN-2fbop985CYu9GaR_m3jAKuNvDNebv-P6nd3xy2yN_hIpsg</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Chen, Jing</creator><creator>Zhang, Yan</creator><creator>Min, Hanchen</creator><creator>Zhi, Junli</creator><creator>Ma, Shuyun</creator><creator>Dong, Hongxia</creator><creator>Yan, Jingshuang</creator><creator>Chi, Xiaoyan</creator><creator>Zhang, Xiaomei</creator><creator>Yang, Yunsheng</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202403</creationdate><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><author>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>16S rRNA sequencing</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteria - classification</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - genetics</topic><topic>Bacteria - isolation & purification</topic><topic>Bismuth</topic><topic>Bismuth - administration & dosage</topic><topic>Bismuth - therapeutic use</topic><topic>bismuth quadruple therapy</topic><topic>Drug Therapy, Combination</topic><topic>Eradication</topic><topic>Feces</topic><topic>Feces - microbiology</topic><topic>Female</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>gut microbiota</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - drug effects</topic><topic>Helicobacter pylori - physiology</topic><topic>high‐dose dual therapy</topic><topic>Histology</topic><topic>Humans</topic><topic>Intestinal microflora</topic><topic>Klebsiella</topic><topic>Male</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Middle Aged</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Relative abundance</topic><topic>RNA, Ribosomal, 16S - genetics</topic><topic>rRNA 16S</topic><topic>Therapy</topic><topic>Urea</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Min, Hanchen</creatorcontrib><creatorcontrib>Zhi, Junli</creatorcontrib><creatorcontrib>Ma, Shuyun</creatorcontrib><creatorcontrib>Dong, Hongxia</creatorcontrib><creatorcontrib>Yan, Jingshuang</creatorcontrib><creatorcontrib>Chi, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Xiaomei</creatorcontrib><creatorcontrib>Yang, Yunsheng</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Helicobacter (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jing</au><au>Zhang, Yan</au><au>Min, Hanchen</au><au>Zhi, Junli</au><au>Ma, Shuyun</au><au>Dong, Hongxia</au><au>Yan, Jingshuang</au><au>Chi, Xiaoyan</au><au>Zhang, Xiaomei</au><au>Yang, Yunsheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</atitle><jtitle>Helicobacter (Cambridge, Mass.)</jtitle><addtitle>Helicobacter</addtitle><date>2024-03</date><risdate>2024</risdate><volume>29</volume><issue>2</issue><spage>e13077</spage><epage>n/a</epage><pages>e13077-n/a</pages><issn>1083-4389</issn><eissn>1523-5378</eissn><abstract>Background
A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT).
Methods
We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing.
Results
Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels.
Conclusion
Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38682268</pmid><doi>10.1111/hel.13077</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1083-4389 |
ispartof | Helicobacter (Cambridge, Mass.), 2024-03, Vol.29 (2), p.e13077-n/a |
issn | 1083-4389 1523-5378 |
language | eng |
recordid | cdi_proquest_miscellaneous_3048497949 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | 16S rRNA sequencing Adolescent Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Bacteria - classification Bacteria - drug effects Bacteria - genetics Bacteria - isolation & purification Bismuth Bismuth - administration & dosage Bismuth - therapeutic use bismuth quadruple therapy Drug Therapy, Combination Eradication Feces Feces - microbiology Female Gastrointestinal Microbiome - drug effects gut microbiota Helicobacter Infections - drug therapy Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - physiology high‐dose dual therapy Histology Humans Intestinal microflora Klebsiella Male Microbiota Microorganisms Middle Aged Proton Pump Inhibitors - administration & dosage Proton Pump Inhibitors - therapeutic use Relative abundance RNA, Ribosomal, 16S - genetics rRNA 16S Therapy Urea Young Adult |
title | Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20changes%20in%20the%20gut%20microbiota%20after%20bismuth%20quadruple%20therapy%20and%20high%E2%80%90dose%20dual%20therapy%20for%20Helicobacter%20pylori%20eradication&rft.jtitle=Helicobacter%20(Cambridge,%20Mass.)&rft.au=Chen,%20Jing&rft.date=2024-03&rft.volume=29&rft.issue=2&rft.spage=e13077&rft.epage=n/a&rft.pages=e13077-n/a&rft.issn=1083-4389&rft.eissn=1523-5378&rft_id=info:doi/10.1111/hel.13077&rft_dat=%3Cproquest_cross%3E3048497949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3048407332&rft_id=info:pmid/38682268&rfr_iscdi=true |